<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503594</url>
  </required_header>
  <id_info>
    <org_study_id>P060239</org_study_id>
    <nct_id>NCT00503594</nct_id>
  </id_info>
  <brief_title>Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine</brief_title>
  <acronym>CNSLymphoma</acronym>
  <official_title>Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two types of chemotherapy for primary central
      nervous system lymphoma in the elderly (age older than 60) :

        -  Methotrexate, procarbazine, vincristine and cytarabine

        -  Methotrexate and temozolomide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate efficacy and toxicity associated with both protocols in
      this population, without radiotherapy.

      Patients will be randomized to receive one of the two regimens in one of the participating
      centers. Neuropsychological evaluation will be performed in all patients. Patients will be
      followed with serial MRIs.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival:median and overall survival</measure>
    <time_frame>at one and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>at end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>2 to 5 years after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bras conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bras conventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate and temozolomide</intervention_name>
    <description>Methotrexate and temozolomide</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate , procarbazine ,vincristine ,cytarabine</intervention_name>
    <description>Methotrexate , procarbazine ,vincristine ,cytarabine</description>
    <arm_group_label>bras conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary central nervous system lymphoma histologically confirmed by brain biopsy, CSF
             cytology or vitrectomy

          -  KPS 40 or higher

          -  Absence of systemic disease as evaluated by chest-abdomen-pelvis CT scan

          -  Leucocytes&gt;3.500/mm3, platelets&gt;130.000/mm3, Bilirubin &lt; 2 mg, transaminases &lt; 2.5 N),
             creatinine &lt; 150 μM/l, creatinine clearance &gt; 40 ml/min

          -  Age ≥ 60 years

          -  Negative HIV test

          -  Signature of informed consent

        Exclusion Criteria:

          -  previous cranial radiotherapy

          -  prior chemotherapy for primary central nervous system lymphoma

          -  presence of another cancer (excepting basal cell carcinoma of the skin and cervical
             carcinoma in situ )

          -  systemic lymphoma (outside the CNS)

          -  Isolated ocular lymphoma

          -  Immunosuppressed patients (HIV , use of immunosuppressors)

          -  Other uncontrolled or progressive disease compromising shot-term survival

          -  Severe renal or hepatic disease

          -  Patients not legally covered by the French Social Security

          -  Inability to swallow the medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio OMURO, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio OMURO, MD,PhD</last_name>
    <phone>+ 33(0) 1 42 16 41 60</phone>
    <email>antonio.omuro@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe hospitalier la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio OMURO, MD,PhD</last_name>
      <phone>+ 33(0) 1 42 16 41 60</phone>
      <email>antonio.omuro@psl.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov</url>
    <description>A review on chemotherapy options for primary central nervous system lymphoma</description>
  </link>
  <results_reference>
    <citation>Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus. 2006 Nov 15;21(5):E12. Review.</citation>
    <PMID>17134114</PMID>
  </results_reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary central nervous system lymphoma</keyword>
  <keyword>Brain lymphoma</keyword>
  <keyword>Elderly</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Procarbazine</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

